Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Differential immune response induced by two immunization schedules with an inactivated SARS-CoV-2 vaccine in a randomized phase 3 clinical trial

Nicolás MS Gálvez, View ORCID ProfileGaspar A Pacheco, Bárbara M Schultz, View ORCID ProfileFelipe Melo-González, Jorge A Soto, Luisa F Duarte, Liliana A González, Daniela Rivera-Pérez, Mariana Ríos, Roslye V Berríos, Yaneisi Vázquez, Daniela Moreno-Tapia, Omar P Vallejos, Catalina A Andrade, Guillermo Hoppe-Elsholz, Carolina Iturriaga, Marcela Urzua, María S Navarrete, Álvaro Rojas, Rodrigo Fasce, Jorge Fernández, Judith Mora, Eugenio Ramírez, Aracelly Gaete-Argel, Mónica Acevedo, View ORCID ProfileFernando Valiente-Echeverría, Ricardo Soto-Rifo, Daniela Weiskopf, Alba Grifoni, Alessandro Sette, Gang Zeng, Weining Meng, CoronaVac03CL Study Group, José V González-Aramundiz, David Goldblatt, Pablo A González, Katia Abarca, Susan M Bueno, View ORCID ProfileAlexis M Kalergis
doi: https://doi.org/10.1101/2022.08.05.22278464
Nicolás MS Gálvez
1Millennium Institute on Immunology and Immunotherapy
2Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gaspar A Pacheco
1Millennium Institute on Immunology and Immunotherapy
2Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Gaspar A Pacheco
Bárbara M Schultz
1Millennium Institute on Immunology and Immunotherapy
2Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Felipe Melo-González
1Millennium Institute on Immunology and Immunotherapy
2Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile
3Departamento de Ciencias Biológicas, Facultad de Ciencias de la Vida, Universidad Andrés Bello, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Felipe Melo-González
Jorge A Soto
1Millennium Institute on Immunology and Immunotherapy
2Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile
3Departamento de Ciencias Biológicas, Facultad de Ciencias de la Vida, Universidad Andrés Bello, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luisa F Duarte
1Millennium Institute on Immunology and Immunotherapy
2Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Liliana A González
1Millennium Institute on Immunology and Immunotherapy
2Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniela Rivera-Pérez
1Millennium Institute on Immunology and Immunotherapy
2Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mariana Ríos
1Millennium Institute on Immunology and Immunotherapy
2Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roslye V Berríos
1Millennium Institute on Immunology and Immunotherapy
2Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yaneisi Vázquez
1Millennium Institute on Immunology and Immunotherapy
2Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniela Moreno-Tapia
1Millennium Institute on Immunology and Immunotherapy
2Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Omar P Vallejos
1Millennium Institute on Immunology and Immunotherapy
2Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Catalina A Andrade
1Millennium Institute on Immunology and Immunotherapy
2Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guillermo Hoppe-Elsholz
1Millennium Institute on Immunology and Immunotherapy
2Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carolina Iturriaga
4Departamento de Enfermedades Infecciosas e Inmunología Pediátrica, División de Pediatría, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marcela Urzua
4Departamento de Enfermedades Infecciosas e Inmunología Pediátrica, División de Pediatría, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
María S Navarrete
5Departamento de Enfermedades Infecciosas del Adulto, División de Medicina, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Álvaro Rojas
5Departamento de Enfermedades Infecciosas del Adulto, División de Medicina, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rodrigo Fasce
6Departamento de Laboratorio Biomédico, Instituto de Salud Pública de Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jorge Fernández
6Departamento de Laboratorio Biomédico, Instituto de Salud Pública de Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Judith Mora
6Departamento de Laboratorio Biomédico, Instituto de Salud Pública de Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eugenio Ramírez
6Departamento de Laboratorio Biomédico, Instituto de Salud Pública de Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aracelly Gaete-Argel
7Laboratory of Molecular and Cellular Virology, Virology Program, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mónica Acevedo
7Laboratory of Molecular and Cellular Virology, Virology Program, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fernando Valiente-Echeverría
7Laboratory of Molecular and Cellular Virology, Virology Program, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Fernando Valiente-Echeverría
Ricardo Soto-Rifo
7Laboratory of Molecular and Cellular Virology, Virology Program, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniela Weiskopf
8Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alba Grifoni
8Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alessandro Sette
8Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA
9Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego (UCSD), La Jolla, CA 92037, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gang Zeng
10Sinovac Biotech, Beijing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Weining Meng
10Sinovac Biotech, Beijing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
José V González-Aramundiz
11Departamento de Farmacia, Facultad de Química y de Farmacia. Pontificia Universidad Católica de Chile, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Goldblatt
12Department of Infection, Inflammation and Immunity, Great Ormond Street Institute of Child Health, University College London, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pablo A González
1Millennium Institute on Immunology and Immunotherapy
2Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katia Abarca
1Millennium Institute on Immunology and Immunotherapy
4Departamento de Enfermedades Infecciosas e Inmunología Pediátrica, División de Pediatría, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susan M Bueno
1Millennium Institute on Immunology and Immunotherapy
2Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: sbueno@bio.puc.cl akalergis@bio.puc.cl
Alexis M Kalergis
1Millennium Institute on Immunology and Immunotherapy
2Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile
13Departamento de Endocrinología, Facultad de Medicina, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Alexis M Kalergis
  • For correspondence: sbueno@bio.puc.cl akalergis@bio.puc.cl
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background The development of vaccines to control the COVID-19 pandemic progression is a worldwide priority. CoronaVac® is an inactivated SARS-CoV-2 vaccine approved for emergency use with robust efficacy and immunogenicity data reported in trials in China, Brazil, Indonesia, Turkey, and Chile.

Methods This study is a randomized, multicenter, and controlled phase 3 trial in healthy Chilean adults aged ≥18 years. Volunteers received two doses of CoronaVac® separated by two (0-14 schedule) or four weeks (0-28 schedule). 2,302 volunteers were enrolled, 440 were part of the immunogenicity arm, and blood samples were obtained at different times. Samples from a single center are reported. Humoral immune responses were evaluated by measuring the neutralizing capacities of circulating antibodies. Cellular immune responses were assessed by ELISPOT and flow cytometry. Correlation matrixes were performed to evaluate correlations in the data measured.

Results Both schedules exhibited robust neutralizing capacities with the response induced by the 0-28 schedule being better. No differences were found in the concentration of antibodies against the virus and different variants of concern between schedules. Stimulation of PBMCs with MPs induced the secretion of IFN-γ and the expression of activation induced markers for both schedules. Correlation matrixes showed strong correlations between neutralizing antibodies and IFN-γ secretion.

Conclusions Immunization with CoronaVac® in Chilean adults promotes robust cellular and humoral immune responses. The 0-28 schedule induced a stronger humoral immune response than the 0-14 schedule.

Funding Ministry of Health, Government of Chile, Confederation of Production and Commerce & Millennium Institute on Immunology and Immunotherapy, Chile.

Clinical trial number NCT04651790.

summary Two immunization schedules were evaluated for the inactivated SARS-CoV-2 vaccine, Coronavac®, with two doses of the vaccine separated by two or four weeks. We compared humoral and cellular immune responses, showing they are mostly similar, with differences in neutralization capacities.

Competing Interest Statement

R.S-R. reports funding from FONDECYT 1190156 and ANID - ICM, ICN 2021_045. A.S. is a consultant for Gritstone Bio, Flow Pharma, ImmunoScape, Moderna, AstraZeneca, Avalia, Fortress, Repertoire, Gilead, Gerson Lehrman Group, RiverVest, MedaCorp, and Guggenheim. LJI has filed for patent protection for various aspects of T cell epitope and vaccine design work. A.S., A.G., and D.W. are under NIH contract 75N9301900065. Z.G. and M.W. are SINOVAC employees and contributed to the conceptualization of the study (clinical protocol and eCRF design). ZG and MW did not participate in the analysis or interpretation of the data presented in the manuscript. The Agencia Nacional de Investigación y Desarrollo (ANID) - Millennium Science Initiative Program - ICN09_016 / ICN 2021_045: Millennium Institute on Immunology and Immunotherapy (former P09/016-F) and Agencia Nacional de Investigación y Desarrollo [FONDECYT grant numbers 1190830] supports S.M.B, P.A.G., and A.M.K. S.M.B acts as the Scientific Director of clinical trials PedCoronaVac03CL clinical study (ClinicalTrials.gov NCT04992260) and CoronaVac03CL (ClinicalTrials.gov NCT04651790). S.M.B. reports funding from the Agencia Nacional de Invetsigación y Desarrollo, Fondo de Fomento al Desarrollo Científico y tecnológico ID20I10082. P.A.G acts as the Executive Director of the clinical trials PedCoronaVac03CL clinical study (ClinicalTrials.gov NCT04992260) and CoronaVac03CL (ClinicalTrials.govNCT04651790). A.M.K acts as the General Director of clinical trials PedCoronaVac03CL clinical study (ClinicalTrials.gov NCT04992260) and CoronaVac03CL (ClinicalTrials.gov NCT04651790). All other authors declare no potential conflict of interest.

Clinical Trial

NCT04651790

Funding Statement

This work was supported by: The Ministry of Health, Government of Chile supported the funding of the CoronaVac03CL Study; The Confederation of Production and Commerce (CPC), Chile, supported the funding of the CoronaVac03CL Study; The Millennium Institute on Immunology and Immunotherapy, ANID - Millennium Science Initiative Program ICN09_016 (former P09/016-F) supports SMB, KA, PAG, and AMK; The Innovation Fund for Competitiveness FIC-R 2017 (BIP Code: 30488811-0) supports SMB, PAG, and AMK; FONDECYT grants N° 1190156 awarded to RSR, and N° 1180798 awarded to FVE; the NIH NIAID under Contract No. 75N93021C00016 supports AS and Contract No. 75N9301900065 supports AS, DW. SINOVAC Life Science Co contributed to this study with the investigational vaccine and placebo, and experimental reagents. The funding sources had no role in the study design, collection, analysis, and interpretation of data, writing of this manuscript, or the decision to submit it. All authors confirm they have full access to all the data and accept responsibility to submit for publication.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

NAMES, AFFILIATIONS AND RESPONSE OF ETHICAL COMMITTEES 1. Full names and affiliations: Comité Ético Científico Ciencias de la Salud UC, Pontificia Universidad Católica de Chile, Santiago, Chile; Comité Ético Científico Universidad de Los Andes, Santiago, Chile; Comité Ético Científico Facultad de Medicina Clínica Alemana, Universidad del Desarrollo, Santiago, Chile; Comité Ético Científico Hospital Clínico Félix Bulnes, Santiago, Chile; Comité Ético Científico Servicio de Salud Valparaíso-San Antonio, Valparaíso, Chile; Comité Ético Científico Servicio de Salud Metropolitano Sur Oriente, Santiago, Chile 2. Decision of all CEC was: Approval

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All raw data (anonymized to protect the information of volunteers) is included with the publication of this article as a supporting file. Source Data File 1 contains the numerical data used to generate all the figures. The study protocol is also available online and was previously published in doi: 10.1101/2021.03.31.21254494.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted August 08, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Differential immune response induced by two immunization schedules with an inactivated SARS-CoV-2 vaccine in a randomized phase 3 clinical trial
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Differential immune response induced by two immunization schedules with an inactivated SARS-CoV-2 vaccine in a randomized phase 3 clinical trial
Nicolás MS Gálvez, Gaspar A Pacheco, Bárbara M Schultz, Felipe Melo-González, Jorge A Soto, Luisa F Duarte, Liliana A González, Daniela Rivera-Pérez, Mariana Ríos, Roslye V Berríos, Yaneisi Vázquez, Daniela Moreno-Tapia, Omar P Vallejos, Catalina A Andrade, Guillermo Hoppe-Elsholz, Carolina Iturriaga, Marcela Urzua, María S Navarrete, Álvaro Rojas, Rodrigo Fasce, Jorge Fernández, Judith Mora, Eugenio Ramírez, Aracelly Gaete-Argel, Mónica Acevedo, Fernando Valiente-Echeverría, Ricardo Soto-Rifo, Daniela Weiskopf, Alba Grifoni, Alessandro Sette, Gang Zeng, Weining Meng, CoronaVac03CL Study Group, José V González-Aramundiz, David Goldblatt, Pablo A González, Katia Abarca, Susan M Bueno, Alexis M Kalergis
medRxiv 2022.08.05.22278464; doi: https://doi.org/10.1101/2022.08.05.22278464
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Differential immune response induced by two immunization schedules with an inactivated SARS-CoV-2 vaccine in a randomized phase 3 clinical trial
Nicolás MS Gálvez, Gaspar A Pacheco, Bárbara M Schultz, Felipe Melo-González, Jorge A Soto, Luisa F Duarte, Liliana A González, Daniela Rivera-Pérez, Mariana Ríos, Roslye V Berríos, Yaneisi Vázquez, Daniela Moreno-Tapia, Omar P Vallejos, Catalina A Andrade, Guillermo Hoppe-Elsholz, Carolina Iturriaga, Marcela Urzua, María S Navarrete, Álvaro Rojas, Rodrigo Fasce, Jorge Fernández, Judith Mora, Eugenio Ramírez, Aracelly Gaete-Argel, Mónica Acevedo, Fernando Valiente-Echeverría, Ricardo Soto-Rifo, Daniela Weiskopf, Alba Grifoni, Alessandro Sette, Gang Zeng, Weining Meng, CoronaVac03CL Study Group, José V González-Aramundiz, David Goldblatt, Pablo A González, Katia Abarca, Susan M Bueno, Alexis M Kalergis
medRxiv 2022.08.05.22278464; doi: https://doi.org/10.1101/2022.08.05.22278464

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (269)
  • Allergy and Immunology (549)
  • Anesthesia (135)
  • Cardiovascular Medicine (1749)
  • Dentistry and Oral Medicine (238)
  • Dermatology (172)
  • Emergency Medicine (310)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (654)
  • Epidemiology (10785)
  • Forensic Medicine (8)
  • Gastroenterology (584)
  • Genetic and Genomic Medicine (2935)
  • Geriatric Medicine (286)
  • Health Economics (531)
  • Health Informatics (1919)
  • Health Policy (833)
  • Health Systems and Quality Improvement (743)
  • Hematology (290)
  • HIV/AIDS (627)
  • Infectious Diseases (except HIV/AIDS) (12501)
  • Intensive Care and Critical Care Medicine (684)
  • Medical Education (299)
  • Medical Ethics (86)
  • Nephrology (322)
  • Neurology (2785)
  • Nursing (150)
  • Nutrition (431)
  • Obstetrics and Gynecology (556)
  • Occupational and Environmental Health (597)
  • Oncology (1458)
  • Ophthalmology (441)
  • Orthopedics (172)
  • Otolaryngology (255)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (380)
  • Pediatrics (865)
  • Pharmacology and Therapeutics (362)
  • Primary Care Research (334)
  • Psychiatry and Clinical Psychology (2633)
  • Public and Global Health (5342)
  • Radiology and Imaging (1004)
  • Rehabilitation Medicine and Physical Therapy (595)
  • Respiratory Medicine (724)
  • Rheumatology (329)
  • Sexual and Reproductive Health (289)
  • Sports Medicine (278)
  • Surgery (327)
  • Toxicology (47)
  • Transplantation (149)
  • Urology (125)